Total Payments
$158,723
2024 Payments
$1,834
Companies
53
Transactions
1,241
Medicare Patients
14,890
Medicare Billing
$1.8M
Payment Breakdown by Category
Other$121,905 (76.8%)
Food & Beverage$23,715 (14.9%)
Travel$7,740 (4.9%)
Consulting$5,219 (3.3%)
Education$144.60 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $121,205 | 100 | 76.4% |
| Food and Beverage | $23,715 | 1,078 | 14.9% |
| Travel and Lodging | $7,740 | 40 | 4.9% |
| Consulting Fee | $5,219 | 5 | 3.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $700.00 | 1 | 0.4% |
| Education | $144.60 | 17 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | $48,031 | 153 | $0 (2024) |
| Lilly USA, LLC | $45,480 | 164 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $28,922 | 104 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $20,923 | 59 | $0 (2021) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $3,133 | 75 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,544 | 87 | $0 (2023) |
| Amgen Inc. | $1,226 | 68 | $0 (2024) |
| Xeris Pharmaceuticals, Inc. | $884.42 | 42 | $0 (2024) |
| Novo Nordisk Inc | $791.56 | 56 | $0 (2022) |
| ABBVIE INC. | $778.27 | 44 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,834 | 87 | Xeris Pharmaceuticals, Inc. ($333.91) |
| 2023 | $9,806 | 149 | Lilly USA, LLC ($7,626) |
| 2022 | $36,674 | 207 | Lilly USA, LLC ($33,204) |
| 2021 | $3,899 | 150 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($1,530) |
| 2020 | $6,932 | 104 | Merck Sharp & Dohme Corporation ($4,397) |
| 2019 | $17,404 | 128 | SANOFI-AVENTIS U.S. LLC ($10,018) |
| 2018 | $44,212 | 205 | SANOFI-AVENTIS U.S. LLC ($19,448) |
| 2017 | $37,962 | 211 | SANOFI-AVENTIS U.S. LLC ($16,500) |
All Payment Transactions
1,241 individual payment records from CMS Open Payments — Page 1 of 50
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $22.05 | General |
| 12/17/2024 | Amneal Pharmaceuticals LLC | UNITHROID (Drug) | Food and Beverage | In-kind items and services | $25.12 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/05/2024 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | In-kind items and services | $25.53 | General |
| Category: Bone Health | ||||||
| 12/03/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $17.45 | General |
| Category: Diabetes | ||||||
| 12/02/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $23.62 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 11/23/2024 | Avvisto Therapeutics, LLC | CYCLOSET (Drug) | Food and Beverage | In-kind items and services | $17.02 | General |
| Category: ANTI-DIABETIC | ||||||
| 11/20/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $23.05 | General |
| Category: Diabetes | ||||||
| 11/19/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $23.99 | General |
| 11/19/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $22.73 | General |
| Category: Diabetes | ||||||
| 11/06/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $14.98 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/06/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $13.54 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/29/2024 | Amneal Pharmaceuticals LLC | UNITHROID (Drug) | Food and Beverage | In-kind items and services | $28.36 | General |
| Category: ENDOCRINOLOGY | ||||||
| 10/29/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $21.92 | General |
| Category: Diabetes Care | ||||||
| 10/24/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $22.89 | General |
| 10/22/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $21.12 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/22/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $20.32 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/18/2024 | Avvisto Therapeutics, LLC | CYCLOSET (Drug) | Food and Beverage | In-kind items and services | $23.79 | General |
| Category: ANTI-DIABETIC | ||||||
| 10/18/2024 | Radius Health, Inc. | Tymlos (Drug) | Food and Beverage | In-kind items and services | $23.53 | General |
| Category: Endocrinology | ||||||
| 10/15/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $107.14 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 10/15/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $25.11 | General |
| Category: Bone Health | ||||||
| 10/09/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $23.42 | General |
| Category: Diabetes | ||||||
| 10/07/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $18.62 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 10/01/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $19.67 | General |
| Category: Diabetes | ||||||
| 09/19/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $17.85 | General |
| 09/17/2024 | Amneal Pharmaceuticals LLC | UNITHROID (Drug) | Food and Beverage | In-kind items and services | $26.28 | General |
| Category: ENDOCRINOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 3,533 | 12,624 | $1.3M | $507,941 |
| 2022 | 22 | 3,457 | 12,414 | $1.0M | $481,316 |
| 2021 | 22 | 3,883 | 11,707 | $972,805 | $501,625 |
| 2020 | 23 | 4,017 | 8,593 | $566,951 | $339,013 |
Total Patients
14,890
Total Services
45,338
Medicare Billing
$1.8M
Procedure Codes
83
All Medicare Procedures & Services
83 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 903 | 2,010 | $470,200 | $217,190 | 46.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 59 | 5,880 | $294,000 | $108,732 | 37.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 525 | 845 | $158,950 | $67,011 | 42.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 224 | 580 | $145,818 | $42,737 | 29.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 1,117 | 2,365 | $52,608 | $18,945 | 36.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 159 | 159 | $34,221 | $16,144 | 47.2% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 123 | 248 | $29,000 | $11,606 | 40.0% |
| 95250 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | Office | 2023 | 45 | 46 | $28,750 | $6,586 | 22.9% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 149 | 200 | $25,000 | $6,366 | 25.5% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 58 | 60 | $16,650 | $4,771 | 28.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 32 | 33 | $10,800 | $4,039 | 37.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 65 | 118 | $5,310 | $1,423 | 26.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 15 | 21 | $1,575 | $1,107 | 70.3% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 18 | 18 | $792.00 | $647.64 | 81.8% |
| 90688 | Influenza vaccine, quadrivalent, 0.5 ml dosage | Office | 2023 | 18 | 18 | $720.00 | $368.28 | 51.2% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 23 | 23 | $2,024 | $266.76 | 13.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 965 | 2,266 | $445,568 | $244,358 | 54.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 53 | 5,520 | $276,000 | $94,287 | 34.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 398 | 533 | $76,975 | $41,861 | 54.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 217 | 566 | $88,296 | $37,367 | 42.3% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 174 | 539 | $40,089 | $19,594 | 48.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 136 | 136 | $25,568 | $13,974 | 54.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 1,114 | 2,401 | $14,406 | $7,065 | 49.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 36 | 37 | $8,847 | $4,670 | 52.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 27 | 27 | $6,200 | $4,280 | 69.0% |
About Dr. Rory Breidbart, MD
Dr. Rory Breidbart, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in New Hyde Park, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1285600973.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rory Breidbart, MD has received a total of $158,723 in payments from pharmaceutical and medical device companies, with $1,834 received in 2024. These payments were reported across 1,241 transactions from 53 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($121,205).
As a Medicare-enrolled provider, Breidbart has provided services to 14,890 Medicare beneficiaries, totaling 45,338 services with total Medicare billing of $1.8M. Data is available for 4 years (2020–2023), covering 83 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism|Endocrinology, Diabetes & Metabolism
- Location New Hyde Park, NY
- Active Since 02/23/2006
- Last Updated 04/30/2025
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1285600973
Products in Payments
- MOUNJARO (Drug) $34,635
- JARDIANCE (Drug) $32,925
- SOLIQUA (Drug) $21,884
- TOUJEO (Drug) $17,339
- STEGLATRO (Drug) $13,982
- SOLIQUA 100/33 (Drug) $6,598
- CYCLOSET (Drug) $3,271
- JANUVIA (Drug) $2,317
- JANUMET (Drug) $1,945
- TOUJEO (Biological) $1,536
- FARXIGA (Drug) $1,520
- UNITHROID (Drug) $797.00
- EVENITY (Biological) $789.15
- Tymlos (Biological) $599.81
- Vascepa (Drug) $534.56
- SOLIQUA 100/33 (Biological) $472.66
- GVOKE HYPOPEN (Drug) $401.69
- INVOKANA (Drug) $386.48
- AFREZZA (Drug) $375.82
- Ozempic (Drug) $362.16
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in New Hyde Park
Isaac Sachmechi, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $435,377
Endocrinology, Diabetes & Metabolism $435,377
Kenneth Hershon, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $140,805
Endocrinology, Diabetes & Metabolism $140,805
Stuart Weinerman, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $53,888
Endocrinology, Diabetes & Metabolism $53,888
Russell Dambra, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $4,596
Endocrinology, Diabetes & Metabolism $4,596
Angella Mashkabova, Pa, PA
Endocrinology, Diabetes & Metabolism — Payments: $3,804
Endocrinology, Diabetes & Metabolism $3,804
Ronda Bloom, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $3,630
Endocrinology, Diabetes & Metabolism $3,630